HEARTCARE-B (06609) rose over 11%, and as of writing, the stock was up 11.17% to HK$60.7, with a turnover of HK$7.6481 million. On the news front, on December 12, 2025, HEARTCARE-B announced its intention to place 1 million domestic shares to Zhang Han at a 1.10% discount, raising a net amount of HK$43.25 million. China Securities Co., Ltd. pointed out that after the expected completion of the transaction, the company's liquid cash reserves are projected to be further bolstered; this cash is anticipated to be fully utilized by the end of 2028 for investments or acquisitions within the medical device industry, which is expected to expand the company's product portfolio and support its long-term sustainable growth. The firm believes that this increase in shareholding by company executives using their own funds demonstrates management's confidence in the progress of the company's A-share IPO and its medium to long-term strategic development. Previously, on September 15, 2025, the company announced via its official WeChat account that the kick-off meeting for its A-share IPO was successfully held, indicating that the company may further enhance its capital market liquidity through a future A-share listing. Furthermore, the company is actively advancing the medical device registration process for its invasive brain-computer interface product, with the first human clinical enrollment expected to be completed by the end of 2026.